These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 2126686)
1. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Anwar H; Costerton JW Antimicrob Agents Chemother; 1990 Sep; 34(9):1666-71. PubMed ID: 2126686 [TBL] [Abstract][Full Text] [Related]
2. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Anwar H; Strap JL; Chen K; Costerton JW Antimicrob Agents Chemother; 1992 Jun; 36(6):1208-14. PubMed ID: 1416820 [TBL] [Abstract][Full Text] [Related]
3. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. Anwar H; Dasgupta M; Lam K; Costerton JW J Antimicrob Chemother; 1989 Nov; 24(5):647-55. PubMed ID: 2513307 [TBL] [Abstract][Full Text] [Related]
4. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa. Cabezudo I; Pfaller M; Bale M; Wenzel R Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048 [TBL] [Abstract][Full Text] [Related]
5. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa]. Yamashiro Y; Ogake N; Takahata M; Minami S Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299 [TBL] [Abstract][Full Text] [Related]
6. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Chan EL; Zabransky RJ Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156 [TBL] [Abstract][Full Text] [Related]
7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528 [TBL] [Abstract][Full Text] [Related]
8. Transient exposure to a physiologically-relevant concentration of calcium confers tobramycin resistance upon sessile cells of Pseudomonas aeruginosa. Hoyle BD; Costerton JW FEMS Microbiol Lett; 1989 Aug; 51(3):339-41. PubMed ID: 2511067 [TBL] [Abstract][Full Text] [Related]
9. Eradication of biofilm cells of Staphylococcus aureus with tobramycin and cephalexin. Anwar H; Strap JL; Costerton JW Can J Microbiol; 1992 Jul; 38(7):618-25. PubMed ID: 1393831 [TBL] [Abstract][Full Text] [Related]
10. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Takahashi K; Kanno H Antimicrob Agents Chemother; 1984 Nov; 26(5):789-91. PubMed ID: 6440482 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of synergistic enhancement of antimicrobial activities of piperacillin and amikacin against Pseudomonas aeruginosa using FIC index and disc diffusion method]. Uete T; Matsuo K Jpn J Antibiot; 1990 Sep; 43(9):1572-8. PubMed ID: 2124633 [TBL] [Abstract][Full Text] [Related]
12. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301 [TBL] [Abstract][Full Text] [Related]
13. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873 [TBL] [Abstract][Full Text] [Related]
14. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Cappelletty DM; Rybak MJ Antimicrob Agents Chemother; 1996 Mar; 40(3):677-83. PubMed ID: 8851592 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli. Fass RJ Antimicrob Agents Chemother; 1982 Jun; 21(6):1003-6. PubMed ID: 6810755 [TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Hyatt JM; Nix DE; Stratton CW; Schentag JJ Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906 [TBL] [Abstract][Full Text] [Related]
17. In vitro comparison of mezlocillin and piperacillin plus tobramycin or gentamicin versus 100 gram-negative nosocomial bloodstream isolates. Cabezudo I; Pfaller MA; Barrett M; Bale M; Wenzel RP Am J Infect Control; 1990 Aug; 18(4):250-6. PubMed ID: 2403216 [TBL] [Abstract][Full Text] [Related]
18. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis]. Bertrou A; Marty N; Henry S; Agueda L; Chabanon G Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the interaction between piperacillin and ciprofloxacin or tobramycin against thirteen strains of Pseudomonas aeruginosa, using killing curves. Fuursted K; Gerner-Smidt P Acta Pathol Microbiol Immunol Scand B; 1987 Jun; 95(3):193-7. PubMed ID: 3115061 [TBL] [Abstract][Full Text] [Related]